Results 321 to 330 of about 9,202,004 (415)

Efficacy of 0.05% cyclosporine A on tear inflammatory cytokines and goblet cell function after corneal refractive surgery. [PDF]

J Ophthalmic Inflamm Infect
Qian W, Wu Y, Liu X, Liu Y, Li M, Zhao T, Chen N, Ke B.   +7 more
europepmc   +1 more source

Intraocular lens power calculation accuracy in patients with keratoconus: Network meta‐analysis and systematic review

Clinical &Experimental Ophthalmology, EarlyView.
Abstract Background Accurate intraocular lens (IOL) calculation in eyes with keratoconus (KCN) poses significant challenges. While various formulas, including KCN‐specific ones, have been investigated, the optimal calculation method remains inconclusive. Methods The study was pre‐registered in PROSPERO (CRD42023483119).
Olga Reitblat, Ruti Sella, Rita Zlatkin, Irit Bahar, Tsahi T. Lerman   +4 more
wiley   +1 more source

Bilateral corneoscleritis with retrocorneal plaque as the initial presentation of granulomatosis with polyangiitis. [PDF]

BMC Ophthalmol
Liu J, Zhang B.
europepmc   +1 more source

Eyes Offshore: Reporting the Eye Health Needs of Refugees and Asylum Seekers in Australia's Offshore Detention Centres

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background In the last two decades, over 250 000 refugees and asylum seekers have arrived in Australia, many of whom experience significant health problems. Information about their eye health is scarce, particularly for those detained offshore. This is the first study to explore the eye health and services available to this population, helping
Marcel M. Nejatian, Rosie Dawkins, Ebrar Al‐Yasery, Hessom Razavi   +3 more
wiley   +1 more source

Ocular surface glycocalyx in health and disease. [PDF]

Front Cell Dev Biol
Martínez-Carrasco R, Sharma A.
europepmc   +1 more source

Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta‐Analysis

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To identify evidence on the use of topical CsA for ocular surface diseases (OSD). Methods A literature search was conducted following the preferred reporting items for systematic reviews and meta‐analyses (PRISMA) through June 2023 via Cochrane Central Registries, Clinical Trials Registry, Grey literature and citation searching ...
Ngozi C. Chidi‐Egboka, Leo Fan, Maria Qureshi, Chameen Samarawickrama, Fiona Stapleton, Tanya Trinh, Maria Markoulli, Elsie Chan, Jern Yee Chen, Jason Holland, Stephanie L. Watson   +10 more
wiley   +1 more source

Presumed Autoimmune Keratitis in Both Eyes Without Systemic Manifestations: A 40-Year Course of a Patient With Corneal Infiltrates and Melt. [PDF]

Cureus
Matsuo T, Tanaka T.
europepmc   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

To evaluate the effects of artificial tears on ocular biological parameters in dry eye and non-dry eye patients. [PDF]

Sci Rep
Chen Y, Li M, Chen J, Zhao J, Pazo EE, Qin G, He X.   +6 more
europepmc   +1 more source

Genetic Association of Primary Angle‐Closure Glaucoma and Disease Progression

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To investigate single‐nucleotide polymorphisms (SNPs) reported in the largest up‐to‐date systematic review and meta‐analysis on primary angle‐closure disease (PACD), on their associations with primary angle‐closure glaucoma (PACG) and disease progression.
Yu Jing Liang, Anni Ling, Poemen P. Chan, Jason C. Yam, Chi Pui Pang, Clement C. Tham, Li Jia Chen   +6 more
wiley   +1 more source